Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics

30-Jan-2009 - Dako has entered into a collaboration with OSI Pharmaceuticals, Inc. Under the terms of agreement, Dako and OSI Pharmaceuticals, Inc. will collaborate on developing a new cancer diagnostic test as a potential companion product for a cancer therapy. The new cancer diagnostic test is intended to ...

Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response

Abbott's FISH Technology Provides Analytical Tool with Potential to Assess Clinical Response to Lung Cancer Treatment in Patients with Non-Small-Cell Lung Cancer

11-Mar-2008 - Abbott announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva(R) (erlotinib), an oral tablet indicated for the ...

Dako enters new collaboration on targeted therapies for non-small cell lung cancer

22-Aug-2007 - Dako has entered into collaboration with Genentech, OSI and Roche for the clinical development and application for a Premarket Approval Supplement (sPMA) and CE marking of EGFR pharmDx for use of the EGFR pharmDx test as a potential aid in the assessment of non-small cell lung cancer (NSCLC) ...

OSI Pharmaceuticals: Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer

01-Aug-2006 - OSI Pharmaceuticals, Inc. announced that Roche, its international partner for Tarceva(R) (erlotinib), received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP), regarding approval of Tarceva in combination with gemcitabine chemotherapy as first-line, ...

OSI Pharmaceuticals Announces Submission of New Drug Application for Tarceva(R) in Japan

19-Apr-2006 - OSI Pharmaceuticals, Inc. announced that a New Drug Application has been submitted in Japan covering the use of its flagship product, Tarceva(R) (erlotinib), for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). The application was submitted to the Japanese Ministry of ...

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement

23-Aug-2005 - OSI Pharmaceuticals, Inc. and Eyetech Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement whereby OSI has agreed to acquire Eyetech, a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics to treat eye diseases. ...

OSI Pharmaceuticals Announces Acquisition of All Minority Interest Shares of Prosidion Limited

20-Apr-2005 - OSI Pharmaceuticals, Inc. announced that it has completed a stock-for-stock exchange resulting in the acquisition of all minority interest shares of the Company's majority-owned UK-based diabetes and obesity subsidiary, Prosidion Limited. A total of 84,940 new shares of OSIP were issued in ...